Ultragenyx Reports the First Patient Dosing of Setrusumab (UX143) in P-II/III (Orbit) Study for the Treatment of Osteogenesis Imperfecta
Shots:
- The first patient has been dosed in a P-II/III (Orbit) study that evaluates the effect of setrusumab vs PBO in a ratio (1:1:1) & (2:1) in 36 & 195 patients, respectively aged 5 to <26yrs. with OI. The study is designed to study fracture risk reduction in a younger population
- The study is based on the results from the 12mos. P-IIb (ASTEROID) study showed a clear, dose-dependent & significant effect on bone formation & bone density at multiple anatomical sites
- The therapy is also being evaluated in a P-III study in patients aged 2 to <5yrs. for OI over 12 to 24mos. with an expected initiation in H2’22. The company also plans to continue studying setrusumab in adult patients aged 25yrs. with OI
Ref: Globe Newswire | Image: Ultragenyx
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
